LONDON, April 28, 2025 (GLOBE NEWSWIRE) — Spur Therapeutics today announced that it will share new data from its gene therapy programs in Gaucher disease, GBA1 Parkinson’s disease and adrenomyeloneuropathy in oral and poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting being held May 13-17, 2025, in New Orleans. The oral presentation will showcase clinical and preclinical durability data on FLT201, Spur’s adeno-associated virus (AAV) gene therapy candidate for Gaucher disease, which is expected to begin a Phase 3 trial this year. Details of the oral presentation are below: Title: Durability of FLT201: An Investigational Gene Therapy for Gaucher Disease Type 1 Encoding an Engineered Variant of the GCase EnzymeSession: Disease Models and Pre-Clinical Applications for Lysosomal Storage DiseasesDate & Time: Thursday, May 15, 2025, 9:00am CTLocation: Room 291-292Presenter: Rose Sheridan, PhD, Spur Therapeutics Details of the poster presentations are below: Title: SPR301: Dose-dependent Reduction of Inflammation and Substrates in a Surrogate Model for GBA1-linked NeuroinflammationSession: Tuesday Poster ReceptionPoster Number: 522Date & Time: Tuesday, May 13, 2025, 6:00-7:30pm CTLocation: Poster Hall I2Presenter: Rose Sheridan, PhD, Spur Therapeutics Title: Initial Safety Results from the PROPEL Trial Evaluating SBT101 as a Potential Gene Therapy for Spinal Cord Disease in Adult Males with X-linked AdrenoleukodystrophySession: Tuesday Poster ReceptionPoster Number: 857Date & Time: Tuesday, May 13, 2025, 6:00-7:30pm CTLocation: Poster Hall I2Presenter: Philip Yin, MD, PhD, Spur Therapeutics Abstracts are now available on the ASGCT website. About Spur TherapeuticsSpur Therapeutics is a clinical-stage biotechnology company focused on developing life-changing gene therapies for debilitating chronic conditions. By optimizing every component of its product candidates, Spur aims to unlock the true potential of gene therapy to realize outsized clinical results. Spur is advancing a breakthrough gene therapy candidate for Gaucher disease, a potential first-in-class gene therapy candidate for adrenomyeloneuropathy and a preclinical gene therapy candidate for Parkinson’s disease, as well as a research strategy to move gene therapy into more prevalent diseases, including forms of dementia and cardiovascular disease. Expanding our impact, and advancing the practice of genetic medicine. Toward life-changing therapies, and brighter futures. Toward More™ For more information, visit www.spurtherapeutics.com or connect with Spur on LinkedIn and X. Investor ContactNaomi Aokinaomi.aoki@spurtherapeutics.com+ 1 617 283 4298 Media ContactCarolyn Noyescarolyn.noyes@spurtherapeutics.com+ 1 617 780 2182